β-carboline compounds, including Harmine, inhibit DYRK1A and Tau phosphorylation at multiple Alzheimer's disease-related sites

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Frost, Danielle ^a,c   Meechoovet, Bessie ^a,c   Wang, Tong ^a   Gately, Stephen ^a   Giorgetti, Marco ^b   Shcherbakova, Irina ^b   Dunckley, Travis ^a,c  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b MediProPharma Inc   (United States)

^c ARIZONA ALZHEIMER S CONSORTIUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 ETHYLHARMINE; BETA CARBOLINE; BETA CARBOLINE DERIVATIVE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; HARMALINE; HARMAN; HARMINE; HARMOL; MOCLOBEMIDE; MPP 021; MPP 313; PHOSPHOTRANSFERASE; SERINE; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG; CARBOLINE DERIVATIVE; DYRK KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ALZHEIMER DISEASE; ARTICLE; CATALYSIS; CELL CULTURE; CHROMOSOME 21; CONTROLLED STUDY; DOWN SYNDROME; DRUG MECHANISM; DYRK1A GENE; ENZYME INHIBITION; GENE; GENE LOCATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; DRUG EFFECT; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

ALZHEIMER DISEASE; BLOTTING, WESTERN; CARBOLINES; CELL LINE, TUMOR; HARMINE; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TAU PROTEINS;

EID: 79955827792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019264     Document Type: Article

References (22)

1. Altafaj X, Dierssen M, Baamonde C, Marti E, Visa J, et al. (2001) Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet 10: 1915-1923.
2. Ahn KJ, Jeong HK, Choi HS, Ryoo SR, Kim YJ, et al. (2006) DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol Dis 22: 463-472.
3. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, et al. (2007) The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 16: 15-23.
4. Park J, Yang EJ, Yoon JH, Chung KC, (2007) Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome. Mol Cell Neurosci 36: 270-279.
5. Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, et al. (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem 104: 1333-1344.
6. Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, et al. (2007) DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 282: 34850-34857.
7. Azorsa DO, Robeson RH, Frost D, Meec hoovet B, Brautigam GR, et al. (2010) High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. BMC Genomics 11: 25.
8. Wegiel J, Dowjat K, Kaczmarski W, Kuchna I, Nowicki K, et al. (2008) The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol 116: 391-407.
9. Vazquez-Higuera JL, Sanchez-Juan P, Rodriguez-Rodriguez E, Mateo I, Pozueta A, et al. (2009) DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort. BMC Med Genet 10: 129.
10. Glennon RA, Dukat M, Grella B, Hong S, Costantino L, et al. (2000) Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend 60: 121-132.
11. Du W, Aloyo VJ, Harvey JA, (1997) Harmaline competitively inhibits [3H]MK-801 binding to the NMDA receptor in rabbit brain. Brain Res 770: 26-29.
12. Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H, (2010) beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 48: 839-845.
13. Arib O, Rat P, Molimard R, Chait A, Faure P, et al. (2010) Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons. Eur J Pharmacol 629: 47-52.
14. Yang YJ, Lee JJ, Jin CM, Lim SC, Lee MK, (2008) Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. Eur J Pharmacol 587: 57-64.
15. Pimpinella G, Palmery M, (1995) Interaction of beta-carbolines with central dopaminergic transmission in mice: structure-activity relationships. Neurosci Lett 189: 121-124.
16. Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, et al. (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. Febs J 276: 6324-6337.
17. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
18. Jayaprakash V, Sinha BN, Ucar G, Ercan A, (2008) Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg Med Chem Lett 18: 6362-6368.
19. Gustke N, Steiner B, Mandelkow EM, Biernat J, Meyer HE, et al. (1992) The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Lett 307: 199-205.
20. Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, et al. (1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y Acad Sci 777: 96-106.
21. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, et al. (2010) Phosphorylation of Tau at Thr212, Thr231, and Ser262 Combined Causes Neurodegeneration. J Biol Chem 285: 30851-30860.
22. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT, (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103: 26-35.